IMGT, the International ImMunoGeneTics Information System

Lefranc, Marie‐Paule

doi:10.1101/pdb.top115

Cited by 288 publications

(311 citation statements)

References 51 publications

Supporting

Mentioning

309

Contrasting

Unclassified

Order By: Relevance

“…Productive rearrangements, J usage, and CDR3a regions were defined by comparing nucleotide sequences with the reference sequences from IMGTs, the international ImMunoGeneTics information systems (http://www.imgt.org; IMGT/HighV-QUEST). 61,62 Diversity was calculated as ''effective number of sequences'' by the exponential of Shannon index.…”

Section: Methodsmentioning

confidence: 99%

Foxp3+ T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation

et al. 2016

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Foxp3+ T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation

et al. 2016

View full text Add to dashboard Cite

“…Sequences were analyzed using the IMGT databases 25,26 and the IMGT/V-QUEST tool (version 3.2.17, Université Montpellier 2, CNRS, LIGM, Montpellier, France). 27 In order to ensure consistency, sequence data deriving from our previous studies were re-analyzed along with the new data as detailed in the Supplementary Information.…”

Section: Pcr Amplification Of Ighv --Ighd --Ighj Rearrangementsmentioning

confidence: 99%

Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications

et al. 2012

View full text Add to dashboard Cite

We performed an immunogenetic analysis of 345 IGHV --IGHD --IGHJ rearrangements from 337 cases with primary splenic small B-cell lymphomas of marginal-zone origin. Three immunoglobulin (IG) heavy variable (IGHV) genes accounted for 45.8% of the cases (IGHV1-2, 24.9%; 12.8%; 8.1%). Particularly for the IGHV1-2 gene, strong biases were evident regarding utilization of different alleles, with 79/86 rearrangements (92%) using allele *04. Among cases more stringently classified as splenic marginal-zone lymphoma (SMZL) thanks to the availability of splenic histopathological specimens, the frequency of IGHV1-2*04 peaked at 31%. The IGHV1-2*04 rearrangements carried significantly longer complementaritydetermining region-3 (CDR3) than all other cases and showed biased IGHD gene usage, leading to CDR3s with common motifs. The great majority of analyzed rearrangements (299/345, 86.7%) carried IGHV genes with some impact of somatic hypermutation, from minimal to pronounced. Noticeably, 75/79 (95%) IGHV1-2*04 rearrangements were mutated; however, they mostly (56/75 cases; 74.6%) carried few mutations (97 --99.9% germline identity) of conservative nature and restricted distribution. These distinctive features of the IG receptors indicate selection by (super)antigenic element(s) in the pathogenesis of SMZL. Furthermore, they raise the possibility that certain SMZL subtypes could derive from progenitor populations adapted to particular antigenic challenges through selection of VH domain specificities, in particular the IGHV1-2*04 allele.

show abstract

“…The homoduplex bands were excised and purified from the polyacrylamide gel and further sequenced using the DYEnamic ET Terminator Cycle Sequencing Kit (GE Healthcare, formerly Amersham Biosciences, Chalfont St. Giles, UK) on an ABI 310 Automated Sequencer (Applied Biosystems, Foster City, CA) or BigDye 1 Terminator v3.1 Cycle Sequencing Kit on an ABI 3100 Automated Sequencer (LifeTechnologies, formerly Applied Biosystems, Foster City, CA). The sequences obtained were identified using IMGT/V-QUEST software (http://www.IMGT.org/ IMGT_vquest/share/textes/) [18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Lineage switch in childhood acute leukemia: An unusual event with poor outcome

Rossi¹,

Bernasconi²,

Alonso³

et al. 2012

American J Hematol

125

114

View full text Add to dashboard Cite

Although rarely, switches between lymphoid and myeloid lineages may occur during treatment of acute leukemias (AL). Correct diagnosis relies upon confirmation by immunophenotyping of the lineage conversion and certification that the same cytogenetic/molecular alterations remain despite the phenotypic changes. From a total of 1,482 AL pediatric patients, we report nine cases of lineage conversion (0.6%), seven from lymphoid (four Pro-B, two Pre-B, one Common) to myelo-monocytic, and two from myeloid (bilineal, with myeloid predominance) to Pro-B. Eight patients were infants. Switches were suggested by morphology and confirmed with a median of 15 days (range: 8 days-6 months) from initiation of therapy. Of note, in five cases switches occurred before day 15. Stability of the clonal abnormalities was assessed by cytogenetic, RT-PCR/Ig-TCR rearrangement studies in all patients. Abnormalities in 11q23/MLL gene were detected in seven cases. Treatment schedules were ALL (two pts), Interfant-99 (five pts) and AML (two pts) protocols. Despite changing chemotherapy according to the new lineage, all patients died. Our findings support the association of lineage switches with MLL gene alterations and the involvement of a common lymphoid B-myeloid precursor. New therapies should be designed to address these rare cases. Possible mechanisms implicated are discussed. Am. J. Hematol. 87:890-897, 2012. V

show abstract

IMGT, the International ImMunoGeneTics Information System

Cited by 288 publications

References 51 publications

Foxp3+ T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation

Foxp3+ T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation

Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications

Lineage switch in childhood acute leukemia: An unusual event with poor outcome

Contact Info

Product

Resources

About